EGFR-mutant NSCLC constitutes one of the major paradigms of integrating liquid biopsy testing in the clinical setting that is validated through the liquid biopsy tests already approved by the FDA [142]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.